<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1451">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04372017</url>
  </required_header>
  <id_info>
    <org_study_id>PEPCOH</org_study_id>
    <nct_id>NCT04372017</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection</brief_title>
  <official_title>Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanford Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanford Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, double-blind, randomized, placebo-controlled study in two distinct&#xD;
      cohorts to evaluate the efficacy and safety of hydroxychloroquine in the prevention of&#xD;
      COVID-19 infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 14, 2020</start_date>
  <completion_date type="Anticipated">June 4, 2021</completion_date>
  <primary_completion_date type="Actual">June 4, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort A: Percentage of COVID-19 exposed healthcare workers treated with hydroxychloroquine with a positive COVID-19 test.</measure>
    <time_frame>At enrollment completion outcome 1 will be analyzed.</time_frame>
    <description>Determine whether post-exposure prophylaxis with hydroxychloroquine can prevent COVID-19 in healthcare workers who have been exposed to a known case of COVID-19.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort B: Percentage of COVID-19 exposed high-risk individuals treated with hydroxychloroquine with a positive COVID-19 test.</measure>
    <time_frame>At enrollment completion outcome 2 will be analyzed.</time_frame>
    <description>Determine whether post-exposure prophylaxis with hydroxychloroquine can prevent COVID-19 in high-risk individuals who have been exposed to a known case of COVID-19.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV 2</condition>
  <arm_group>
    <arm_group_label>Cohort A: Healthcare worker (hydroxychloroquine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A: Healthcare worker (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: High-Risk participant (hydroxychloroqine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: High-Risk participant (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Participants randomized to hydroxychloroquine will take 800mg on day 1 followed by 400mg on days 2-5.</description>
    <arm_group_label>Cohort A: Healthcare worker (hydroxychloroquine)</arm_group_label>
    <arm_group_label>Cohort B: High-Risk participant (hydroxychloroqine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Participants randomized to placebo will take IU1600 on day 1 and IU 800 on days 2-5.</description>
    <arm_group_label>Cohort A: Healthcare worker (placebo)</arm_group_label>
    <arm_group_label>Cohort B: High-Risk participant (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria Cohort A:&#xD;
&#xD;
          -  ≥ 18 years old&#xD;
&#xD;
          -  Employee of healthcare organization in South Dakota or Sanford Health employee in any&#xD;
             location and with exposure to a person with COVID-19 within the last 5 days&#xD;
&#xD;
               -  Occupational exposure as determined by the participant's employee health&#xD;
                  department (i.e. not wearing the proper Personal Protective Equipment (PPE))&#xD;
&#xD;
               -  Criteria according to Center for Disease Control (CDC) guidelines&#xD;
&#xD;
               -  Community exposure (within 6 feet for at least 15 minutes)&#xD;
&#xD;
          -  No current symptoms attributable to COVID-19, per HCW report (fever, cough, difficulty&#xD;
             breathing, sore throat)&#xD;
&#xD;
          -  No prior COVID-19 positive diagnosis (eligible if previous testing is negative and&#xD;
             meets all other inclusion and exclusion)&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Inclusion Criteria - Cohort B&#xD;
&#xD;
          -  ≥ 18 years old&#xD;
&#xD;
          -  High-risk person who had close contact (i.e. within 6 feet for at least 15 minutes)&#xD;
             with a COVID-19 positive person within the last 5 days and is a South Dakota resident&#xD;
             or high-risk person with close household contact of a COVID-19 positive Sanford&#xD;
             employee&#xD;
&#xD;
          -  High-risk person defined by:&#xD;
&#xD;
          -  Age 18-44 with 2 or more comorbidities listed below&#xD;
&#xD;
          -  Age 45-79 with any comorbid condition listed below&#xD;
&#xD;
          -  Age 80 and above (regardless of comorbid conditions)&#xD;
&#xD;
          -  Co-morbid list&#xD;
&#xD;
               -  Congestive Heart Failure (CHF)&#xD;
&#xD;
               -  Chronic lung disease (Includes any of the following: asthma, chronic obstructive&#xD;
                  pulmonary disease, emphysema)&#xD;
&#xD;
               -  Solid organ transplant or immunosuppression (Defined as an outpatient&#xD;
                  prescription of greater than 10 mg/day of prednisone or equivalent, use of&#xD;
                  chemotherapy, or use of immunosuppressive agents for solid organ transplant or&#xD;
                  for an autoimmune disease.)&#xD;
&#xD;
               -  Chronic Kidney Disease or End Stage Renal Disease&#xD;
&#xD;
               -  Diabetes mellitus&#xD;
&#xD;
               -  Cardiovascular disease/Hypertension&#xD;
&#xD;
               -  Smoking/Vaping (currently using or history of using in the past 1 year)&#xD;
&#xD;
               -  Obesity (calculated by height and weight per participant report)&#xD;
&#xD;
               -  Hyperlipidemia&#xD;
&#xD;
          -  No current symptoms attributable to COVID-19&#xD;
&#xD;
          -  No prior COVID-19 positive diagnosis (eligible if previous testing is negative and&#xD;
             meets all other inclusion and exclusion)&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Confirmed review of concomitant medications (with emphasis on cardiac medications)&#xD;
&#xD;
        Exclusion Criteria Cohort A &amp; B:&#xD;
&#xD;
          -  Known allergy to hydroxychloroquine or quinine&#xD;
&#xD;
          -  Known history of long QT syndrome&#xD;
&#xD;
          -  Known history of arrhythmia or dysrhythmia&#xD;
&#xD;
          -  Known current QTc &gt;500 ms&#xD;
&#xD;
          -  Known G6PD deficiency&#xD;
&#xD;
          -  Known history of hypoglycemia&#xD;
&#xD;
          -  Pregnant or Nursing by patient history&#xD;
&#xD;
          -  Use of any of the following concomitant medications: See Appendix D for Exclusion&#xD;
             medication list&#xD;
&#xD;
          -  Concurrent diagnosis of dermatitis, porphyria, or psoriasis&#xD;
&#xD;
          -  History of chronic liver disease, including cirrhosis and/or diagnosis of hepatitis&#xD;
             (infectious, idiopathic, or immune)&#xD;
&#xD;
          -  History of chronic kidney disease&#xD;
&#xD;
          -  Pre-existing retinopathy&#xD;
&#xD;
          -  Already taking hydroxychloroquine&#xD;
&#xD;
          -  Any condition or medication in the opinion of the investigator that would prohibit the&#xD;
             use of hydroxychloroquine&#xD;
&#xD;
          -  Enrollment in another clinical with investigational drug or device&#xD;
&#xD;
          -  Inability to swallow pills&#xD;
&#xD;
          -  Adults unable to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Hoover, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sanford Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanford Health</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 25, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

